Ranibizumab (Lucentis®) Injection

Lucentis (ranibizumab) is covered for FDA‑approved indications (neovascular/wet AMD, RVO‑related macular edema, DME, DR, mCNV) and certain compendial off‑label neovascular ophthalmic uses, with no explicit exclusions listed. Approval requires ophthalmologist administration/supervision, intravitreal dosing per indication (0.5 mg monthly for wet AMD/RVO, 0.3 mg monthly for DME/DR, 0.5 mg monthly for up to 3 doses for mCNV), and is authorized for up to 12 months.

"Neovascular (wet) age-related macular degeneration (AMD)"

Sign up to see full coverage criteria, indications, and limitations.